-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Training Program Directors Workshop

Program: Special-Interest Sessions
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Workforce, Education
Friday, December 6, 2024: 9:00 AM-12:00 PM
Indigo 204 (Hilton San Diego Bayfront)
Chair:
Pallawi Torka, Roswell Park Cancer Center
Disclosures:
Torka: ADC Therapeutics: Consultancy; Genentech: Consultancy; GenMab: Consultancy; Kura Oncology: Membership on an entity's Board of Directors or advisory committees; Lilly USA: Consultancy; Seagen: Consultancy; TG Therapeutics: Consultancy.

The Training Program Director’s Workshop is held each year before the ASH annual meeting and is designed for training program directors, associate program directors, and others involved with hematology training. The workshop is designed for hematology program directors to share lessons learned, best practice, and explore opportunities to improve their leadership skills. Through experiential learning techniques, breakout sessions, and interactive lectures, program directors can learn from peers and build their network. At this year’s TPDW, we will focus on three opportune topics. First, we will discuss how to design and implement innovative curriculums which can prepare trainees to excel at various aspects of hematology oncology practice beyond just knowledge of the subject matter. Examples of such curriculums include ‘leadership training’, ‘how to be a good educator’, and ‘business of hematology-oncology’. Second, we will focus on best practices for a training program to leverage social media and build their ‘brand’. Lastly, we will discuss practical ways in which programs can help trainees land their dream job.

Scott Moerdler, MD

Pediatric Hematology Oncology, Rutgers Cancer Institute, New Brunswick, NJ

Layla N Van Doren, MD, MBA

Section of Hematology, Division of Medicine, Yale School of Medicine, New Haven, CT

Angela C Weyand, MD

Department of Pediatrics and Communicable Diseases, Division of Pediatric Hematology and Oncology, University of Michigan, Ann Arbor, MI

Gerald Hsu, MD, PhD

University of California, San Francisco, San Francisco, CA

Sunandana Chandra, MD

Northwestern University, Chicago, IL